Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Interest Income
Income earned on cash, deposits, and investments held by the company.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Interest Income · Q3 FY2026 · quarter ended Sep 2026
Interest income growth accelerates
Q3 FY2026 interest income of $16.5M rose 166.4% year over year, ahead of the +34.8% change in trailing-twelve-month interest income. Sequentially, it rose 257.4% from the prior quarter. Over 3 fiscal years it compounded at +106.9% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +166.4% holds above the trailing-twelve-month pace of +34.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 23.61M USD
- Year-over-year change
- -5.6%
- 4-year CAGR
- +176.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.61M | -5.6% |
| FY2024 | 2024-12-31 | 25.02M | +76.3% |
| FY2023 | 2023-12-31 | 14.19M | +432.8% |
| FY2022 | 2022-12-31 | 2.66M | +562.7% |
| FY2021 | 2021-12-31 | 402K | — |
Interest Income vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 interest income of $31.98M is the 2nd highest of the 10 companies compared; the peer median is $9.66M.
- Its year-over-year change of +34.8% is the 2nd highest of 8, against a peer median of -17.0%.
- Over three fiscal years its annual growth of +106.9% compares with a peer median of +59.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $32.68M | +6.8% | +117.1% | — | |
| LTM Sep 2026 | $31.98M | +34.8% | +106.9% | — | |
| LTM Mar 2026 | $30.91M | -51.9% | -11.0% | 1.4% | |
| LTM Mar 2026 | $13.26M | -32.7% | — | 231.0% | |
| LTM Mar 2026 | $10.88M | -17.0% | +64.0% | 33.9% | |
| LTM Mar 2026 | $9.66M | +6.0% | +55.9% | — | |
| LTM Mar 2026 | $8.43M | +242.7% | +128.9% | — | |
| LTM Mar 2026 | $4.15M | -36.5% | +12.9% | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding EWTX) | $9.66M | -17.0% | +59.9% | 17.7% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.